Notice: Applications, Hearings, Determinations, Etc.: Noramco Inc.

43814 Federal Register / Vol. 71, No.
148 / Wednesday, August 2, 2006 / Notices
controlled substances listed in should be addressed, in quintuplicate, may file comments or objections to the
Schedules II: to the Deputy Assistant Administrator, issuance of the proposed registration
Office of Diversion Control, Drug pursuant to 21 CFR § 1301.33(a).
Drug Schedule Enforcement Administration, Any such written comments or
Washington, DC. 20537, Attention: DEA objections being sent via regular mail
Methylphenidate (1724) ................ II may be addressed, in quintuplicate, to
Federal Register Representative/ODL; or
Phenylacetone (8501) .................. II
Methadone intermediate (9254) ... II any being sent via express mail should the Deputy Assistant Administrator,
be sent to DEA Headquarters, Attention: Office of Diversion Control, Drug
The company plans to manufacture DEA Federal Representative/ODL, 2401 Enforcement Administration,
the listed controlled substance in bulk Jefferson-Davis Highway, Alexandria, Washington, DC. 20537, Attention: DEA
for sale to its customer. Virginia 22301; and must be filed no Federal Register Representative, Liaison
Any other such applicant and any later than October 2, 2006. and Policy Section (ODL); or any being
person who is presently registered with Dated: July 26, 2006. sent via express mail should be sent to
DEA to manufacture such a substance DEA Headquarters, Attention: DEA
Joseph T. Rannazzisi,
may file comments or objections to the Federal Register Representative/ODL,
Deputy Assistant Administrator, Office of
issuance of the proposed registration 2401 Jefferson-Davis Highway,
Diversion Control, Drug Enforcement
pursuant to 21 CFR 1301.33(a). Administration. Alexandria, Virginia 22301; and must be
Any such written comments or filed no later than October 2, 2006.
[FR Doc. E6–12457 Filed 8–1–06; 8:45 am]
objections being sent via regular mail BILLING CODE 4410–09–P Dated: July 26, 2006.
should be addressed, in quintuplicate, Joseph T. Rannazzisi,
to the Deputy Assistant Administrator, Deputy Assistant Administrator, Office of
Office of Diversion Control, Drug DEPARTMENT OF JUSTICE Diversion Control, Drug Enforcement
Enforcement Administration, Administration.
Washington, DC. 20537, Attention: DEA Drug Enforcement Administration [FR Doc. E6–12459 Filed 8–1–06; 8:45 am]
Federal Register Representative/ODL; or BILLING CODE 4410–09–P
any being sent via express mail should Manufacturer of Controlled
be sent to DEA Headquarters, Attention: Substances; Notice of Application
DEA Federal Register Representative/ Pursuant to Section 1301.33(a) of Title DEPARTMENT OF JUSTICE
ODL, 2401 Jefferson-Davis Highway, 21 of the Code of Federal Regulations
Alexandria, Virginia 22301; and must be Drug Enforcement Administration
(CFR), this is notice that on February 19,
filed no later than October 2, 2006. 2006, Orasure Technologies, Inc., Manufacturer of Controlled
Dated: July 26, 2006. Lehigh University, Seeley G. Mudd- Substances; Notice of Application
Joseph T. Rannazzisi, Building 6, Bethlehem, Pennsylvania
Deputy Assistant Administrator, Office of 18015, made application by renewal, Pursuant to Section 1301.33(a) of Title
Diversion Control, Drug Enforcement and by letter, to the Drug Enforcement 21 of the Code of Federal Regulations
Administration. Administration (DEA) to be registered as (CFR), this is notice that on January 10,
[FR Doc. E6–12455 Filed 8–1–06; 8:45 am] a bulk manufacturer of the basic classes 2006, Siegfried (USA), Inc., Industrial
BILLING CODE 4410–09–P of controlled substances listed in Park Road, Pennsville, New Jersey
Schedule I and II: 08070, made application by renewal to
the Drug Enforcement Administration
DEPARTMENT OF JUSTICE Drug Schedule (DEA) to be registered as a bulk
manufacturer of the basic classes of
Drug Enforcement Administration Lysergic acid diethylamide (LSD) I controlled substances listed in Schedule
(7315). II:
Manufacturer of Controlled 4–Methoxyamphetamine (7411) ... I
Substances; Notice of Application Normorphine (9313) ..................... I
Drug Schedule
Tetrahydrocannabinols (THC) I
Pursuant to Section 1301.33(a) Title (7370). Amphetamine (1100) .................... II
21 of the Code of Federal Regulations Alphamethadol (9605) .................. I Methylphenidate (1724) ................ II
(CFR), this is notice that on June 27, Amphetamine (1100) .................... II Amobarbital (2125) ....................... II
2006, Noramco Inc., 1440 Olympic Methamphetamine (1105) ............ II Pentobarbital (2270) ..................... II
Drive, Athens, Georgia 30601, made Cocaine (9041) ............................. II Secobarbital (2315) ...................... II
application by letter to the Drug Hydromorphone (9150) ................ II Glutethimide (2550) ...................... II
Benzoylecgonine (9180) ............... II Codeine (9050) ............................. II
Enforcement Administration (DEA) for
Hydrocodone (9193) ..................... II Oxycodone (9143) ........................ II
registration as a bulk manufacturer of Morphine (9300) ........................... II
basic drug code (1724) Hydromorphone (9150) ................ II
Oxycodone (9143) ........................ II Hydrocodone (9193) ..................... II
methylphenidate. Meperidine (9230) ........................ II Methadone (9250) ........................ II
The company plans to bulk Methadone (9250) ........................ II Methadone intermediate (9254) ... II
manufacture methylphenidate for a Oxymorphone (9652) ................... II Dextropropoxyphene, bulk (non- II
customer to use in the production of a dosage forms) (9273).
controlled substance product. The company plans to manufacture Morphine (9300) ........................... II
Any other such applicant and any the listed controlled substances in bulk
person who is presently registered with to manufacture controlled substance The company plans to manufacture
DEA to manufacture such a substance derivatives. These derivatives will be the listed controlled substances in bulk
wwhite on PROD1PC61 with NOTICES
may file comments or objections to the used in diagnostic products created for distribution to its customers.
issuance of the proposed registration specifically for internal use only. Any other such applicant and any
pursuant to 21 CFR 1301.33(a). Any other such applicant and any person who is presently registered with
Any such written comments or person who is presently registered with DEA to manufacture such a substance
objections being sent via regular mail DEA to manufacture such a substance may file comments or objections to the
VerDate Aug<31>2005 16:40 Aug 01, 2006 Jkt 208001 PO 00000 Frm 00105 Fmt 4703 Sfmt 4703 E:\FR\FM\02AUN1.SGM 02AUN1

Notice: Applications, Hearings, Determinations, Etc.: Noramco Inc.

Загружено:

Сведения о документе

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

Notice: Applications, Hearings, Determinations, Etc.: Noramco Inc.

Загружено:

Авторское право:

Доступные форматы

43814 Federal Register / Vol. 71, No.

148 / Wednesday, August 2, 2006 / Notices

Вам также может понравиться